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Patentability of Stem Cell Research
Under TRIPS: Can Morality-Based
Exclusions Be Better Defined by
Emerging Customary International Law?
I. INTRODUCTION
Stem cell research is becoming a household term, yet it is very
likely that neither the average citizen nor government legislature
fully comprehends the ethical and legal conundrums which are
now just beginning to plague researchers and global judicial
systems. Because of ethical issues surrounding the use of
embryonic stem cells and cloning, governments have either
enacted strict regulations, neglected to fund research, or have
shunned it entirely. Meanwhile, many companies are striving to
become world leaders in this important field of medicine, as
certain areas of stem cell research show promising results in the
treatment of major illnesses, including heart failure.
In the United States, the perception is that funding
regulations are both tough and limited to very particular methods
and practices. Many believe that due to the dearth of funding for
stem cell research, its potential growth, and development for
critical care treatment seems stunted. As a result of funding
limitations, some private companies have moved to countries
whose government policies on stem cell advancement range from
mere support to active encouragement. For example, a small
company in Bangkok, Thailand, is currently using adult stem cells
to treat patients with heart conditions.' At almost forty thousand
dollars per procedure, and because Thailand is one of the few
countries in the world allowing commercial stem cell treatment,
patients are more than willing to travel from all over the world for
1. Katie LaGrone, Stem Cell Therapy Shows Promise in Heart Patients, ABC7 NEWS
ONLINE, Jan. 12, 2007, http://www.abc-7.com/Articles/readnews.asp?articleid=10583.
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a second chance at life. Consequently, the company is enjoying
both medical and financial success.
Licensing a new technology or practice is understandably
crucial to an inventor's success and motivation. If a private
company is endowed with the ability to develop promising
treatments in critical care medicine by using stem cells, but is
prevented from pursuing these goals due to financial constraints,
the company should be allowed to seek out global investment
opportunities without fear of retribution or restrictions, as long as
it operates in accordance with international law. The World Trade
Organization (WTO) Agreement on Trade-Related Aspects of
Intellectual Property Rights (TRIPS) and related international
agreements are promising solutions in providing inventors
adequate patent protection in the worldwide marketplace.2
However, there is an element of uncertainty in the equation as the
application of TRIPS to the area of stem cell litigation enters
uncharted waters. For instance, the broad discretion given to
Member States to exclude patents based on "ordre public or
morality" under Article 27.2 may conflict with TRIPS's overall
purpose of providing minimal protection of patent rights,
especially where a patent may be within the bounds of customary
international law adhered to by participating parties.
This Comment initially analyzes the current state of law
regarding stem cell research in the international community. It
seeks to discern some of the common roadblocks to the
patentability and funding of emerging stem cell technologies, as
well as the impact of existing legislation on its future proliferation
throughout the global marketplace. Secondly, this Comment
examines the role morality plays in the patentability of stem cell
research, and whether customary international law may help to
supplement interpretation of TRIPS and related agreements.
Finally, this Comment offers suggestions on whether TRIPS is the
best vehicle - as enacted or in a modified form - to serve society's
interest in new and emerging critical care medicine.
2. See generally Agreement on Trade-Related Aspects of Intellectual Property
Rights, Apr. 15, 1994, 108 Stat. 4809, 1869 U.N.T.S. 299 [hereinafter TRIPS]. TRIPS was
originally a part of the General Agreements on Tariffs and Trade (GATT), and was
negotiated towards the end of the Uruguay Round in 1994.
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II. THE ETHICAL CONFUSION AND ITS ENSUING CONTROVERSY
A. What are Stem Cells?
A stem cell is a type of cell that can reproduce itself for long
periods of time and develop into potentially any cell type present
in the body.' When stem cells are injected into the body, evidence
suggests that these cells engage in a "homing" process whereby
they are attracted by and subsequently travel to an injured site.'
The cells then change, or "differentiate," into the mature type of
cell or tissue structure which they can repair.' Because of this
unique regenerative ability, stem cells offer the prospect of
developing therapeutic cell-based treatments to repair or replace
damaged tissues within the body, thereby offering a hope for
curing some of the most debilitating diseases.6
Stem cells are found in the early embryo, fetus, umbilical
cord, and in many tissues of the mature body.7 Generally, there are
two primary types of stem cells: (1) adult stem cells, also known as
somatic stem cells; and (2) embryonic stem cells, also known as
pluripotent stem cells.' Until recently, it was thought that only
embryonic stem cells could be truly pluripotent9 - having the
ability to differentiate into any type of cell of in the body - and
divide and multiply for extended periods of time.'" This is
important because it is easier to harvest the amount of cells
3. See Stem Cell Basics: Introduction, in STEM CELL INFORMATION (Nat'l Inst. of
Health, U.S. Dep't of Health & Hum. Services 2006), http://stemcells.nih.gov/
infolbasicsfbasicsl.asp.
4. NAT'L INST. OF HEALTH, DEP'T OF HEALTH & HUM. SERVICES, STEM CELLS:
SCIENTIFIC PROGRESS AND FUTURE RESEARCH DIRECTIONS 1 (2001), available at
http://stemcells.nih.gov/staticresources/info/scireport[PDFs/fullrptstem.pdf.
5. SELECT COMMITTEE ON STEM CELL RESEARCH, REPORT, 2001-2, H.L. 83-1,
2.2, box 1.
6. Id. 91 2.6.
7. NAT'L INST. OF HEALTH, DEP'T OF HEALTH & HUM. SERVICES, STEM CELLS:
SCIENTIFIC PROGRESS AND FUTURE RESEARCH DIRECTIONS 1 (2001), available at
http://stemcells.nih.gov/staticresources/info/scireport/PDFs/fullrptstem.pdf [hereinafter
STEM CELLS: SCIENTIFIC PROGRESS AND FUTURE RESEARCH DIRECTIONS]; SELECT
COMMITTEE ON STEM CELL RESEARCH, supra note 5, 1 2.2.
8. Stem Cell Basics: Introduction, supra note 3.
9. What are the Similarities and Differences Between Embryonic and Adult Stem
Cells?, in STEM CELL INFORMATION (Nat'l Inst. of Health, U.S. Dep't of Health & Hum.
Services 2006), http://stemcells.nih.gov/info/basics/basics5.htm.
10. What are the Unique Properties of All Stem Cells?, in STEM CELL INFORMATION
(Nat'l Inst. of Health, U.S. Dep't of Health & Hum. Services 2006),
http://stemcells.nih.gov/info/basics/basics2.htm.
505
506 Loy. L.A. Int'l & Comp. L. Rev. [Vol. 29:503
needed for any viable treatment from pluripotent cells." However,
some recent breakthroughs in the area of private adult stem cell
research may make adult stem cell treatments more feasible.'2
Nonetheless, even though there have been no proven therapeutic
treatments on human subjects to date,'3 scientists believe that the
unique abilities of embryonic stem cells must be studied in order to
develop viable treatments to cure diseases.'
B. What are the Ethical Problems Surrounding Embryo Research?
Much of the global controversy regarding stem cell research
centers on the use of embryonic stem cells. Typically, harvesting
embryonic stem cells specifically requires the destruction of a
human embryo," implicating the hotly debated and controversial
issue over at which stage of embryonic development life actually
"begins." One side argues that the embryo is a mere cluster of cells
that enjoys no more moral status than any other cluster of human
cells. 6 On the opposite side is the view that the embryo enjoys the
same right to life, and therefore is placed in the same moral
category, as children or adults.'7
Even among different religious groups, contrasting views
exist. For instance, the Roman Catholic Church, the Islamic
11. SELECT COMMITTEE ON STEM CELL RESEARCH, supra note5, 3.4.
12. Yael Porat et al., Isolation of an Adult Blood-derived Progenitor Cell Population
Capable of Differentiation into Angiogenic, Myocardial and Neural Lineages, 135 BRIT. J.
HAEMATOLOGY 703, 703 (2006). Because adult stem cell research does not involve the
destruction of embryos, the ethical concerns surrounding embryonic research could be
avoided. Gina Kolata, Stem Cell Science Gets Limelight; Now It Needs a Cure, N.Y. TIMES,
Aug. 24, 2004, at Fl. Many argue that adult stem cell research and its potential for
treatment are often overlooked because of confusion with the more popular debate over
embryonic stem cell research. See, e.g., Nacy Gibbs & Alice Park, What a Bush Veto
Would Mean for Stem Cells, TIME, Ju;y 25, 2005; Irving Weissman, Understanding the
Institute for Cancer/Stem Cell Biology and Medicine, STANFORD REPORT, Jan. 22, 2003,
http://news-service.stanford.edu/news/2003/j anuary22/weissman.html.
13. 152 CONG. REC. 93 (daily ed. July 17, 2006) (statement of Sen. Grassley).
14. See, e.g., SELECT COMMITTEE ON STEM CELL RESEARCH, supra note 5, 3.15.
15. Stem cells form as part of earliest stages of development of the embryo, called the
blastocyst. The blastocyst is formed six to seven days after in vitro fertilization or somatic-
cell transfer procedure. The stem cells are then "derived from the inner cell mass of the
blastocyst at a stage before it would [normally] implant in the uterine wall." STEM CELLS:
SCIENTIFIC PROGRESS AND FUTURE RESEARCH DIRECTIONS, supra note 7, at 1; see also
Rick Weiss, Universal Stem Cell Principles Proposed: Rules Would Guide Research Efforts,
WASH. POST, Mar. 2, 2006, at A12.
16. NAT'L BIOETHICS ADVISORY COMM'N, REPORT AND RECOMMENDATIONS OF
THE NATIONAL BIOETHICS ADVISORY COMMISSION 49 (1999).
17. Id.
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Medical Association, and some Christians believe either that life
begins at conception or that, as long as there is not total certainty
as to when it begins, it must be given the benefit of the doubt and
treated as such." Traditional Hindu views are similar in this
regard." Other religious faiths disagree, and thus do not assign full
moral status to an early embryo."
Most governments have carefully weighed the ethical
arguments, domestic abortion laws, international religious views,
and the science behind the ongoing development of an embryo to
determine when the benefit of research can no longer outweigh
the view that the embryo is at a stage deserving of moral regard.2
Nearly all nations, as well as the U.S. National Bioethics Advisory
Commission, take the position that embryonic research should not
be performed on an embryo once initial organized development
begins.22
III. THE RESEARCH DILEMMA
One of the most significant hurdles for embryonic stem cell
research is the existence of a limited number of stem cell lines
from which viable stem cells can be obtained, either for research
or treatment.23 Opponents generally object out of concern that the
large amount of eggs necessary to make mass treatment viable will
result in the use of unethical methods to obtain embryos. For
instance, opponents of California's Proposition 71 argued that
''women may be subjected to the substantial risks of high dose
hormones and egg extraction procedures just for the purpose of
research."2 Another problem is that stem cells harvested from
18. SELECT COMMITTEE ON STEM CELL RESEARCH, supra note 5, 4.18.
19. Id.
20. NAT'L BIOETHICS ADVISORY COMM'N, supra note 16, at 50. Jewish law has been
seen to take a gradualist position in believing that "[p]ersonhood, with its attendant rights
and responsibilities begins at birth." SELECT COMMITTEE ON STEM CELL RESEARCH,
supra note 5, 4.19.
21. See SELECT COMMITTEE ON STEM CELL RESEARCH, supra note 5, 9 4.1-.22; see
also NAT'L BIOETHICS ADVISORY COMM'N, supra note 16, at 99-104.
22. SELECT COMMITTEE ON STEM CELL RESEARCH, supra note 5, 1 4.22; Pil Ryul
Lee, Pre-Embryo Not Equivalent to Human Being?, in ASIAN BIOETHICS IN THE 21ST
CENTURY § 4.1 (Sang-Yong Song et al. eds., 2003); Research Involving Human Embryos
and Prohibition of Human Cloning Act, 2003, § 13 (Austl.).
23. NAT'L BIOETHICS ADVISORY COMM'N, supra note 16, at 8-9.
24. Proposition 71: Argument in Favor, Rebuttal to Argument in Favor, OFFICIAL
VOTER INFO. GUIDE: Nov. 2, 2004 GEN. ELECTION (Cal. Sec'y of State, Sacramento,
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embryos and used for cell-therapy would normally be subject to
immunological rejection," which occurs when the patient's
immune system does not recognize the introduced cells and rejects
them.26 This is a weighty concern; in many instances, such rejection
could prove fatal without a lifetime commitment to
immunosuppressant drugs.
The most practicable suggestion to date, and perhaps also the
most controversial, is to develop stem cell lines using a method
called somatic cell nuclear transfer (SCNT). SCNT is the process
by which the nucleus of an immature egg is removed and
substituted with that of the patient.27 The cell is then electrically
stimulated to begin dividing,' and within the span of a few days
forms a blastocyst, or early embryo. 9 The blastocyst is then
destroyed to harvest new stem cells, just as with a normal embryo."
Because the stem cells were born from the nucleus of the individual
to be treated, the resulting embryonic stem cells are expected to be
completely compatible with the individual's tissue type,3 and thus
would not be rejected by the host immune system. This process is
often referred to as "therapeutic cloning."3 Taken one step
further, a successful pregnancy could result if the SCNT-derived
embryo is transferred to a surrogate mother?' This is the exact
method by which Dolly the sheep was created. 5
Another controversial proposition is to use non-human donor
eggs to create SCNT-derived embryos using human nuclei. 6 This
process is called chimeric therapeutic cloning, and would
supposedly foster a virtually unlimited amount of donor eggs to
Cal.), Aug. 9, 2004, at 72, available at http://www.sos.ca.gov/elections/bp-nov04/
prop_71_argument in-favorrebuttaltoargument injfavor.pdf.
25. See, e.g., SELECT COMMIrrEE ON STEM CELL RESEARCH, supra note 5, 1 2.15;
26. Id.
27. See NAT'L BIOETHICS ADVISORY COMM'N, supra note 16, at 10.
28. See id. at 19; see also Scientific Aspects of Human Animal Cloning (President's
Council on Bioethics, Staff Working Paper No. 2, 2002), available at
http://www.bioethics.gov/background/workpaper2.html.
29. See NAT'L BIOETHICS ADVISORY COMM'N,supra note 16, at 11 fig. 2-3.
30. See id. at 10-11.
31. Id. at 11.
32. Id.; see also SELECT COMMITTEE ON STEM CELL RESEARCH, supra note 5, 5.7
33. This is in contrast with "reproductive cloning," in which the resulting embryo
would then be implanted into a woman's uterus to produce a baby. See SELECT
COMMITTEE ON STEM CELL RESEARCH, supra note 5, 5.8.
34. NAT'L BIOETHICS ADVISORY COMM'N, supra note 16, at 10.
35. Id.
36. Id. at 2, 19.
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produce the quantity needed for extensive research and mass
treatment. 7 This process simultaneously preserves "the potential
for generating tissues and organs for use in cross-species
transplantation (xenotransplantation) in order to treat human
diseases."38 The National Bioethics Advisory Commission noted
that, while it is uncertain "whether the fusing of a human cell with
the egg of a non-human animal would result in a human embryo[,]
'any attempt to create a child through this process would raise
profound ethical concerns and should not be permitted.'".
IV. THE CURRENT STATE OF INTERNATIONAL LAW
Almost every nation has addressed the profound ethical
concerns around stem cell research through either legislation,
international treaty, or by general policy statement. Most nations
have narrowly tailored their laws to impose criminal penalties on
anyone seeking to produce a clone from an SCNT-derived
embryo."0 In 1997, the Council of Europe (EC) established the
Convention on Human Rights and Biomedicine, further restricting
research in the area by implicitly banning the creation of cloned
SCNT-derived embryos with the broad and explicit proclamation
that "[t]he creation of human embryos for research purposes is
prohibited." 1 Currently, the Convention has been signed by thirty-
four European States, of which twenty have already ratified it.
Several signatories, such as Sweden, have yet to complete the
process and ratify the Convention, conceivably due to their current
policies endorsing SCNT research methods. 2 Other countries, such
as the United Kingdom (UK) and Germany, have made deliberate
decisions to refrain from signing the Convention, leaving their own
domestic laws to address the issue until more is known about the
technology."
37. See generally Emily Singer, Lack of Human Eggs Could Hamper US Cloning
Efforts, TECH. REV., June 15, 2006, http://www.technologyreview.com/Biotech/16990.
38. NAT'L BIOETHICS ADVISORY COMM'N, supra note 16, at 16.
39. See id. at 2 (citation omitted).
40. See, e.g., Human Reproductive Cloning Act, 2001, c. 23, § 1 (U.K.); Human
Cloning Prohibition Act of 2003, H.R. 534, 108th Cong. (2003).
41. Convention for the Protection of Human Rights and Dignity of the Human Being
With Regard to the Application of Biology and Medicine art. 18, opened for signature
Apr. 4, 1997, Europ. T.S. 164.
42. See SELECT COMMITTEE ON STEM CELL RESEARCH, supra note 5, T 7.8.
43. See Kara L. Belew, Stem Cell Division: Abortion Law and its Influence on the
Adoption of Radically Different Embryonic Stem Cell Legislation in the United States, the
United Kingdom, and Germany, 39 TEX. INT'L L.J. 479,515 (2004).
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Although there seems to be a clear international consensus on
banning reproductive cloning, the consensus regarding whether
there should be an outright ban on SCNT and therapeutic cloning
for stem cell research remains murky." In March 2005, the United
Nations General Assembly adopted the United Nations (UN)
Declaration on Human Cloning. This Declaration called upon
Member States "to prohibit all forms of human cloning inasmuch
as they are incompatible with the protection of human life.""5
Although the Declaration did not directly confront the issue,
interpretation of the General Assembly's mandate as to how it
would apply to therapeutic cloning was central in the discussions.
This was the primary reason for numerous abstentions from, or
votes against, the Declaration.6 Although there was general
unanimity that reproductive cloning should be banned, most states
wanted an exception set aside for therapeutic cloning in certain
circumstances. 7 Indeed, several Member States voting in favor of
the Declaration did so with the reservation that their
interpretation of the agreement was that it did not apply to
therapeutic cloning.'
A. The Moral Balancing Act
Virtually all nations under the UN umbrella have addressed
the issues surrounding embryonic stem cell research, either by
their ratification of the UN Declaration on Human Cloning or
through their own domestic laws or policy statements. Whether
Member States are acting in "respect of human life" or "human
dignity," all nations seem to share the underlying belief that they
are obligated to balance the ethical concerns of embryonic
research, in any form, with fundamental moral issues."
Additionally, several common themes in the regulation of stem
cell research are pervasive throughout the world. These include
44. See Aurora Plomer, Beyond the HFE Act 1990: The Regulation of Stem Cell
Research in the UK, 10 MED. L. REV. 132, 164 n.2 (2002).
45. Declaration on Human Cloning, G.A. Res. 59/280, U.N. Doc. A/RES/59/280
(Mar. 23, 2005).
46. See Press Release, General Assembly, General Assembly Adopts United Nations
Declaration on Human Cloning by Vote of 84-34-37, U.N. Doc GA/10333 (Aug. 3, 2005).
47. Id.
48. Id.
49. See Rosario M. Isasi et al., Legal and Ethical Approaches to Stem Cell and Cloning
Research: A Comparative Analysis of Policies in Latin America, Asia, and Africa, 32 J.L.
MED. & ETHICS 626, 636-37 (2004).
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the universal prohibition against reproductive cloning, the
prohibition against research on any embryo more than fourteen
days old, the prohibition against embryonic research without
informed donor consent, and the ban on the commercialization of
both embryonic and fetal tissue.
B. Restrictive Nations
Several nations, such as Germany and Canada, simply refuse
to risk making any moral inquiry into whether an embryo is
deserving of the rights of a human being, employing restrictive
regulations over embryonic research. Canada not only refuses
financial funding for stem cell research, but it strictly prohibits the
"creat[ion] [of] an in vitro embryo for any purpose other than
creating a human being,""° thereby broadly excluding any research
other than for infertility treatment. Additionally, Canada forbids
cloning, chimeric research, and any research which "maintains an
embryo outside the body of a female person after the fourteenth
day of its development . . . ," a crime punishable with up to ten
years imprisonment and a fine of five hundred thousand Canadian
dollars.' Germany "ban[s], as a matter of principle, the
importation and utilization of embryonic stem cells,"52 fearing that
even their mere importation would promote human embryo
destruction. The German regulations extend to all German
scientists, whether or not they practice within German territorial
boundaries.53 For example, scientists who e-mail or telephone
cloning instructions to colleagues in other countries can be
imprisoned for three years and fined more than sixty thousand
U.S. dollars. 4 Due to the Nazi legacy of eugenics, any debate over
the potential benefits of stem cell research is almost non-existent.5
50. Assisted Human Reproduction Act, R.S.C., ch. 2, § 5(1)(b) (2004) (Can.).
51. Id.
52. Stammzellgesetz [Stem Cell Act], June 28, 2002, § 1 (F.R.G.).
53. See Weiss, supra note 15, at A12.
54. See Michael Woods, U.S. Relatively Hospitable to Stem-cell Research,
PITTSBURGH POST-GAZETTE, June 5, 2005, Nation & World, at Al, available at
http://www.post-gazette.com/pg/05156/516098.stm.
55. See Mark Henderson, We Need Ethical Guidelines; Junk Medicine; Stem Cell
Research; TIMES (London), Mar. 4, 2006, Features, available at 2006 WLNR 3665223.
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C. Generally Permissive Nations
Asia, for the most part, is at the other end of the spectrum.
China, India, Japan, South Korea, Singapore, Taiwan, and
Thailand have very limited or no regulation at the national level
and grant a great deal of autonomy to medical professionals. 6
Singapore has no current legislation addressing either reproductive
or research cloning, although it has drafted a bill that would
require informed donor consent in any embryonic research and
strictly prohibit any type of reproductive cloning." The Bioethics
Advisory Committee of Singapore has adopted the position that a
human embryo has the status of a "potential human being, but not
the same status as a living child or adult."58 In weighing the value
of embryonic protection with the potential benefits of proposed
research, the Committee issued Recommendations that would
require researchers to (1) secure informed consent from donors
and (2) only conduct experiments on embryos less than fourteen
days old. 9 In addition, the Recommendations would prohibit the
commercialization of embryos and reproductive cloning of any
kind.' Alternatively, Thailand has no official position on stem cell
research, and thus most research there is conducted in a regulatory
vacuum, with scientific guidelines left to the discretion of the
research institutions themselves."l However, Thailand generally
follows the same guidelines as other Asian states, such as imposing
a fourteen day rule.'
Although debate over embryo cloning (including SCNT) has
been spurred by recent legislation in Hong Kong,63 mainland China
has yet to address the ethical and legal implications of embryonic
stem cell research. China seems to be following the Western model
of legislation by "firmly oppos[ing] reproductive cloning" while
56. See Isasi et al., supra note 49, at 627.
57. Id. at 635.
58. BIOETHICS ADVISORY COMM., ETHICAL, LEGAL AND SOCIAL ISSUES IN
HUMAN STEM CELL RESEARCH, REPRODUCTIVE AND THERAPEUTIC CLONING, at iv
(2002), available at http://www.bioethics-singapore.org/resources/reportsl.html.
59. Id. at vii.
60. See id. at viii.
61. See Isasi et al., supra note 49, at 635.
62. Id.
63. See Human Embryo Cloning Prohibited in Hong Kong, STEM CELL WK., Feb. 13,
2006, available at 2006 WLNR 2295482 (discussing Human Reproductive Technology
Ordinance, (2000) Cap. 561, § 15 (H.K.) (not yet operative)). Although the statute is not
yet fully operative, its prohibitions may still adversely impact research in Hong Kong. Id.
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promoting embryonic research through strict control of
therapeutic cloning.' The Chinese South Center Human Genome
Project has passed guidelines supporting research carried out
under the principles of informed consent, and recommends a
"[s]trict prohibition against . . . maintaining researched embryos
more than 14 days."65 The guidelines also recommend forbidding
the buying and selling of embryos and fetal tissue, as well as any
economic rewards to donors.'
In India, "respect for the embryo's moral status can be shown
by careful regulation of conditions of research, safeguards against
commercial exploitation of embryo research, and limiting the time
within which research can be done to 14 days."67 Indeed, India has
drafted guidelines which allow chimeric cloning and other
embryonic research and clinical trials, provided there is informed
donor consent and research is not conducted beyond fourteen
days.' These same guidelines restrict and reserve regulation over
SCNT processes. 9 These guiding principles further recognize the
commercial value of embryonic stem cell lines, and that patent
protection should be recognized on a case-by-case basis.7"
D. Moderate Nations
The UK, in passing the Human Fertilisation and Embryology
Act,71 was surely a pioneer in embryo research regulation. In its
original form the Act allowed the creation of embryos in vitro,
subject to conditions requiring written consent from the donor and
a prohibition on the use or storage of the embryo after fourteen
days.7 The Act further imposed a criminal punishment of up to ten
64. See Isasi et al., supra note 49, at 634-35 (citation omitted); see also China Needs
Law to Prevent Cloning Misuse, PEOPLE'S DAILY ONLINE (P.R.C.), Mar. 12, 2005,
http://english.peopledaily.com.cn/200503/12/eng20O50312_176531.html.
65. Yanguang Wang, Chinese Ethical Views on Embryo (ES) Stem Cell Research, in
ASIAN BIOETHICS IN THE 21ST CENTURY § 3.1 (Sang-Yong Song et al. eds., 2003).
66. Id.
67. CENT. ETHICS COMM. ON HUM. RES., INDIAN COUNCIL OF MED. RES., ETHICAL
GUIDELINES FOR BIOMEDICAL RESEARCH ON HUMAN SUBJECTS 47 (2000), available at
http://www.icmr.nic.in/ethical.pdf.
68. See INDIAN COUNCIL OF MED. RES., NATIONAL GUIDELINES FOR STEM CELL
RESEARCH AND THERAPY 5-6 (2006) (draft), available at http://www.icmr.nic.in
/stemcell/stemcell-guidelines.pdf.
69. Id. at 6.
70. Id. at 12.
71. Human Fertilisation and Embryology Act, 1990, c. 37 (U.K.).
72. Id. §§ 3, 16.
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years of imprisonment for violations.73 In 2001, the UK introduced
regulations expanding the licensing of research into embryo
development, including embryos created by SCNT' Prior to these
regulations, licensing was only available to promote various
developments or treatments in the areas of infertility, congenital
disease and contraception." The position of the UK on SCNT and
its cautiously worded legislation was reached only after lengthy
debate both inside and outside of Parliament on the "special
status" of the embryo.76
The shift away from broader proscriptions on SCNT may be
gaining some momentum. Many other nations have imposed
regulations following or nearly following the format of the
fourteen day rule, informed donor consent, and banning
commercialization of embryonic tissue and reproductive cloning.'
Australia, for instance, has recently modified its previously
restrictive legislation to allow the use of SCNT in therapeutic
cloning."8 The Australian parliament narrowly passed the broader
legislation with strong debate over the moral issues.9 Nevertheless,
research is restricted to embryos that are less than fifteen days old
and that are obtained with proper consent. Any violation of
specifically prohibited research practices could result in
punishment of up to fifteen years imprisonment .
E. The U.S. Approach
The most permissive actor in stem cell research is by far the
United States. Unlike the UK, which tends to steer a middle
73. Id. § 41.
74. See Human Fertilisation and Embryology (Research Purposes) Regulations, 2001,
S.I. 2001/188, art. 2, 1-2 (U.K.); see also R (Quintavalle) v. Secretary of State for
Health, [2002] Q.B. 628, 628.
75. Human Fertilisation and Embryology Act § 11, sched. 2.
76. See SELECT COMMITrEE ON STEM CELL RESEARCH, supra note 5, 1.2, 4.5,
7.10.
77. See id. 7.9 (noting that the Netherlands limits research on an embryo to fifteen
days); see generally Isasi et al., supra note 49 (comparing research policies in Latin
America, Asia, and Africa); see also NAT'L BIOETHICS ADVISORY COMM'N, supra note
16, at 40.
78. See CBS News: Aussie Lawmakers End Ban on Human Cloning (CBS broadcast
Dec. 6, 2006) (Austl.).
79. See id.
80. Prohibition of Human Cloning for Reproduction and the Regulation of Human
Embryo Research Amendment Act, 2006, sched. 2 (2006) (Austl.) (amending Research
Involving Human Embryos Act 2002).
81. Id. sched. 1 (amending Prohibition of Human Cloning Act 2002).
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ground, the United States imposes no criminal liability for
embryonic stem cell research or cloning in any form, and only
seeks to enforce its policy against embryonic stem cell research by
limiting otherwise available federal funding.' Numerous bills have
circulated Congress seeking to either prohibit cloning or support
embryonic stem cell research. With respect to federal legislation,
the battle-lines have been drawn at SCNT and therapeutic cloning,
and each piece of legislation has failed for either its inclusion or
exclusion.83
To date, the only bill to pass both the House and Senate was
vetoed twice by President George W. Bush.' That bill, originally
enacted by Congress as H.R. 810, would have provided federal
support for embryonic stem cell research providing the "stem cells
were derived from human embryos donated from in vitro
fertilization clinics, were created for the purposes of fertility
treatment... were in excess of the clinical need... [, would have]
never be[en] implanted in a woman, [and] donated.., with written
informed consent .. . ." It is noteworthy that this legislation did
not address SCNT research methods. Further, what makes this
piece of legislation distinct is its diversion from the international
norms seen in most other countries - specifically, informed donor
consent to use the embryos for research purposes and a prohibition
against maintaining an embryo for more than fourteen days.
President Bush officially supported research on only those
stem cell lines created before August 9, 2001, but took the position
that H.R. 810 "would support the taking of innocent human life"
and that "America must never abandon [its] fundamental
82. See Michael Woods, U.S. Relatively Hospitable to Stem-cell Research,
PITTSBURGH POST-GAZETTE, June 5, 2005, http://www.post-gazette.com/
pg/05156/516098.stm.
83. See Letter from Indep. Citizens Oversight Comm., Cal. Inst. for Regenerative
Medicine, to Sen. Dianne Feinstein and Sen. Barbara Boxer (Aug. 5, 2005), available at
http://www.cirm.ca.gov/meetings/pdf/2005/08/080505_item_7b.pdf; see also Human
Cloning Prohibition Act of 2005, S. 658, 109th Cong. (2005); Human Cloning Prohibition
Act of 2005, H.R. 1347, 109th Cong. (2005); 152 CONG. REC. 93 (daily ed. July 17, 2006)
(statement of Sen. Grassley).
84. See David Jackson, Bush cites 'moral line' in second veto of stem cell bill, USA
Today, June 21, 2007, http://www.usatoday.com/news/washington/2007-06-20-bush-stem-
cellsN.htm.
85. Stem Cell Research Enhancement Act of 2005, H.R. 810, 109th Cong. § 489D
(2006).
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morals."' Still, most Americans support embryonic stem cell
research, even if the ethical implications of such research and an
understanding of other nations' laws remain unclear.87 The
Democratic leadership came into control of Congress following
the 2006 elections, and as a part of their new mandate,
reintroduced the bill." This time Congress coupled the original
language with an endorsement of non-embryonic stem cell
research,8 and again, the President vetoed the bill citing the same
reasons.' The President pointed to recent advances in alternative
stem cell research and went on to issue an executive order
supporting research that does not require the destruction of
human embryos.9'
In the absence of federal legislation, the Food and Drug
Administration (FDA) has asserted jurisdiction over all stem cell
related matters intended for use in therapeutic treatment. 2
However, FDA regulations do not apply to early embryonic
research not intended for use in the development of a FDA-related
product, and therefore the creation of embryonic stem cell lines by
any means mostly remains unencumbered in the United States.93
Whether therapeutic cloning should be specifically proscribed has
generally been left for the individual states to decide.94 California
has recently adopted a state constitutional amendment which
specifically establishes a fundamental "right to conduct stem cell
research . . . which includes research involving ...[p]luripotent
86. Mary Dalrymple, Bush Vetoes Stem Cell Bill as Promised, BREITBART, July 19,
2006, http://www.breitbart.com/article.php?id=D8lV7E080&showarticle=l.
87. See id.
88. Stem Cell Research Enhancement Act of 2007, S.5, 110th Cong. (2007).
89. See id.
90. See Jackson, supra note 84.
91. See id; Exec. Order No. 13,435, 72 Fed. Reg. 34,591 (June 20, 2007).
92. NAT'L BIOETHICS ADVISORY COMM'N, supra note 16, at 93-95. As early as 1996,
the FDA published guidance stating that "structural cells (autologous cells manipulated
and then returned to the body for structural repair or reconstruction) would be subject to
licensure" as biological products under section 351 of the Public Health Service Act, 42
U.S.C. 262. Id.; CTR. FOR BIOLOGICS EVALUATION & RES., U.S. FED. DRUG ADMIN.,
DOCKET NO. 95N-0200, GUIDANCE ON APPLICATIONS FOR PRODUCTS COMPRISED OF
LIVING AUTOLOGOUS CELLS MANIPULATED Ex VIVO AND INTENDED FOR
STRUCTURAL REPAIR OR RECONSTRUCTION (1996).
93. See NAT'L BIOETHICS ADVISORY COMM'N, supra note 16, at 67, 93.
94. See SELECT COMMITrEE ON STEM CELL RESEARCH, supra note 5, 7 7.11. New
Jersey was the first state to appropriate funds for embryonic stem cell research. Nat'l
Conference of State Legislatures, State Embryonic and Fetal Research Laws,
http://www.ncsl.org/programs/health/Genetics/embfet.htm (last visited Dec. 6, 2006).
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stem cells . derived from somatic cell nuclear transfer or from
surplus products of in vitro fertilization treatments ...donated
under appropriate informed consent procedures."95 Again there is
no reference to a fourteen day restriction. Opponents of the
measure warned of the possibility of human cloning and danger to
women from extraction procedures that might be undertaken
solely for the purpose of research,"° echoing common themes heard
in the global arena.
At the time of this Comment, California, Connecticut,
Massachusetts, New Jersey, and Rhode Island allow therapeutic
cloning in research; Arkansas, Indiana, Iowa, Michigan, North
Dakota, and South Dakota prohibit therapeutic cloning.97
Massachusetts and New Hampshire incorporate a fourteen day
rule into their research laws.98 Apart from current and potential
state and federal legislation, the U.S. National Bioethics Advisory
Commission, established by President Clinton, made strong
recommendations that embryonic, research should be limited to
fourteen days, subject to a donor's informed consent as to whether
her embryo would be used for clinical research, embryonic tissue
should not be bought or sold, and that "federal funding should not
be provided to derive ES cells from [SCNT procedures]."99
V. EMERGING CUSTOMARY INTERNATIONAL LAW
As previously discussed, practically every developed nation in
the world has confronted the morality of embryonic stem cell
research by enacting public ordinances, promulgating guidelines,
or making clear policy statements."'0 The global consensus seems to
be that embryonic research should not be done without informed
donor consent, and should not be conducted on any embryo over
fourteen days old. There is also a general disdain for the potential
commercialization of embryos and other fetal tissue.
These widespread practices suggest the emergence of
customary international law. Customary international law results
from a general and consistent practice, widespread among nations,
95. CAL. CONST. art. XXXV, § 5.
96. Proposition 71: Argument in Favor, Rebuttal to Argument in Favor, supra note 24,
at 72.
97. Id.
98. Id.
99. NAT'L BIOETHICS ADVISORY COMM'N, supra note 16, at v - vi.
100. See supra Part IV.
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that is followed due to a sense of legal obligation (opinio juris sive
necessitats).' There is no universal consensus as to what will
create customary international law in any particular situation; but
it is generally accepted that customary international law is rooted
in government acts, public measures, international agreements
between nations, as well as soft law such as official statements of
policy and guidelines. 2
Certainly, there is enormous international concern over
balancing the ethical dilemma of embryo destruction with the
potential benefit of stem cell research, and it is well understood
that this balance is hard to maintain once the first sign of
organized development begins in an embryo. Based on these
moral principles, nations have explicitly chosen not to allow
embryonic stem cell research past this critical stage.
Unquestionably, the widespread enactment of strict criminal
legislation surrounding embryonic research is based upon both a
moral and legal obligation to basic human rights and human
dignity. This is strong evidence that opinio juris is present. The
same case can be made against the commercialization of
embryonic materials. The buying and selling of embryos is
tantamount to buying and selling body parts, a practice prohibited
by nearly all developed nations;"°3 and the potential for elevating
the restriction to the status of a peremptory norm binding on all
nations should not entirely be ruled out. Alternatively, while there
is a strong prohibition against chimeric implantation in human
subjects, the use of chimeric research on non-human subjects is
still the subject of considerable debate.
Informed consent before medical treatment has already been
deemed a matter of customary international law;" 4 in reviewing the
positions taken by the international community, the principles of
informed consent undoubtedly extend to the context of donors of
embryos which may be used for research purposes. Whether the
use of a donor's egg in a SCNT procedure is subject to informed
consent may be unsettled, but it is certainly the obvious logical
extension of such measures. Despite its absence in select
101. RESTATEMENT (THIRD) OF FOREIGN RELATIONS § 102 (2007).
102. Id.
103. Steve P. Calandrillo, Cash for Kidneys? Utilizing Incentives to End America's
Organ Shortage, 13 GEO. MASON L. REV. 69, 86 (2004).
104. See Michele Forzley et al., International Legal Developments in Review: 1999, 34
INT'L LAW 749,750 (2000).
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legislation (such as that passed in California and New Jersey), °5 the
fourteen day rule remains consistent practice within the
international arena.
Inaction may constitute state practice for the purpose of
forming customary international law. The failure of some states in
adopting a practice, however, will not prevent the creation of a
norm of customary international law for all other participating
regions." No states overtly dissent to the principles described
above.
Moreover, a federal policy in the United States that is
consistent with the policies of other nations could supplement or
alter the "practice" in its own states such as California and New
Jersey. Therefore, the emergence of a norm of customary
international law that generally prohibits research on an embryo
beyond fourteen days should not be precluded in the United
States. It is interesting to see the divergence between bills passed
in the U.S. Congress (and some state legislatures) with regulations
passed by the international community. Arguably, some legislators
are either uninformed as to these international norms or have
made a conscious decision to disregard them altogether, and have
thus missed an enormous opportunity to contribute to customary
international law.
VI. THE IMPORTANCE OF FUNDING AND PATENTS
A. Funding Limitations
On August 9, 2001, U.S. President George W. Bush approved
federal funding for research on stem cell lines which were
cultivated from previously destroyed embryos.17 By allowing the
research to continue without promoting the further destruction of
human embryos, the federal government drew a careful line
between the potential of stem cell research and its moral
implications. Under these restrictions, the United States provides
approximately 40 million dollars annually in federal funding for
105. See S. 1909, 210th Leg., Reg. Sess. (N.J. 2002) (enacting legislation which allows
embryonic stem cell research, including that by SCNT, provided a policy of periodic
review in accordance with applicable federal regulations).
106. See RESTATEMENT (THIRD) OF FOREIGN RELATIONS § 102, cmt. b.
107. See President George W. Bush, President Bush Announces Funding for Limited
Embryonic Stem Cell Research (August 9, 2001), http://www.whitehouse.gov/news
/releases/2001/08/20010809-2.html.
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public research activities involving human embryos.'9 But with
California earmarking 3 billion dollars over the next ten years for
stem cell research, and with New Jersey's investment in a 380
million dollar stem cell institute, the United States still takes the
lead worldwide in funding.'"
The European Union has embraced U.S. federal funding
restrictions, yet it still provides little funding to projects which use
unused embryos created by in vitro fertilization with donor
permission consistent with European law."' Within Europe, the
British government allocated just over 72 million dollars between
2004 and 2006.' While the Chinese government provided roughly
12 million dollars between 2000 and 2005, it further plans to
devote up to 132 million dollars during the next five years."2 With
millions in capital, it seems as though research would be booming,
but this is not entirely the case. No right to federal funding exists
in this area, and there is no federal control of privately funded
research."3
Thus, private institutions may be driven to take the lead. 4 As
of June 2005, American firms engaged in stem cell research have
raised 441 billion dollars from venture capitalists alone."5 The
global pharmaceutical market grew to 602 billion dollars in 2005
and is expected to grow to over 840 billion dollars by 2010. ' 6 These
sales could possibly serve to further embryonic stem cell research
and development."7
108. Nat'l Inst. of Health, U.S. Dep't of Health & Hum. Services, Estimates of Funding
for Various Diseases, Conditions, Research Areas, http://www.nih.gov/news/
fundingresearchareas.htm (last visited Dec. 6, 2006).
109. See Fiona Murray & Debora Spar, Bit Player or Powerhouse? China and Stem
Cell Research, 355 NEW ENG. J. MED. 1191, 1192 (2006), available at
http://content.nejm.org/cgi/reprint/355/12/1191.pdf.
110. See Woods, supra note 82.
111. Murray & Spar, supra note 109, at 1192.
112. Id.
113. SELECT COMMITTEE ON STEM CELL RESEARCH, supra note 5, 1 7.11.
114. Dan Vergano, States Dive Into Stem Cell Debates, USA TODAY, Apr. 20, 2004,
http:lwww.usatoday.com/newslhealthl2004-04-20-stem-cell-coverx.htm.
115. Murray & Spar, supra note 109, at 1192.
116. Edwin Bailey, BioMarket Trends, Overview of the Global Pharmaceutical Market,
GENETIC ENGINEERING NEWS, Aug. 1, 2006, http:/lwww.genengnews.comlarticlesl
chitem.aspx?aid=1820&chid--O.
117. See id.
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B. Importance of Patents in the Biotechnology Industry
Funding of research is often secured through licensing.
Indeed, licensing is vital to the biotechnology industry, "8 and the
area most affected by future legislation will likely be in patent
licensing. Patents grant an inventor an exclusionary right to
prevent others from making, using, selling, offering to sell or
importing the claimed invention for a fixed period of time in
exchange for public disclosure of the invention."9 Biotechnology
patents therefore ensure market exclusivity, and theoretically they
encourage further investment in the technology while stimulating
further research through the free flow of scientific and technical
knowledge. This exchange is further exemplified in the United
States where the government is willing to bestow federal grantees
(such as universities, small businesses, and non-profit
organizations) the right to retain title to inventions in exchange for
an agreement to attempt to commercialize them.2 '
At the domestic level, subject matter is usually not excluded
from patentability for any reason other than the plain meaning of
their patent statutes. 2' This scheme makes sense since patent
examiners are not trained in making ethical decisions regarding
patentability.'22 Moreover, exclusion of subject matter which is
useful in some ways would go against the general intent of patent
laws which is to "promote the Progress of Science and useful
Arts."'23 It should be the legislature who, working on behalf of the
public, defines what is patentable and what is not based upon the
common values of society at large.'24 For instance, in the
pharmaceutical industry, courts generally have recognized that
118. Paul Elias, Court Shakes up Biotech Patent World, FORBES, Jan. 9, 2007,
http://www.forbes.com/feeds/ap/2007/01/09/ap3314966.html.
119. DONALD S. CHISUM, CHISUM ON PATENTS § 1 (Matthew Bender & Co., 2007),
available at LEXIS.
120. See Cal. Inst. for Regenerative Med., Intellectual Property Policy for Non-profit
Organizations 34 (approved Feb. 10, 2006); Act to Amend the Patent and Trademark
Laws, Pub. L. No. 96-517, 94 Stat. 3015 (1980).
121. See Diamond v. Chakrabarty, 447 U.S. 303, 318 ("Congress is free to amend [the
patent laws] as to exclude from patent protection organisms produced by genetic
engineering."); see also Harvard College v. Canada (Commissioner of Patents), [2002] 4
S.C.R. 45, 47.
122. UNITED NATIONS CONFERENCE ON TRADE AND DEV. & INT'L CTR. FOR
TRADE AND SUSTAINABLE DEV., RESOURCE BOOK ON TRIPS AND DEVELOPMENT 380
(2005) [hereinafter UNCTAD & ICTSD].
123. U.S. CONST., art. I, § 8, cl. 8.
124. See UNCTAD & ICTSD, supra note 122, at 380.
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balancing the risks of new, unproven medicines with the possibility
of saving lives is not the job of the patent office, and the
requirements for use and distribution of drugs are quite different
from the requirements for patentability.'25 It should be noted that
while the possibility of critical care therapy derived from
embryonic stem cells is still unproven, no one is willing to say that
the "substantial" utility requirement for patentability has not been
met or that stem cells cannot "provide some immediate benefit to
the public.' 26
A patent does not exempt the owner from regulation or
prohibition,'27 and thusly patented stem cell lines or processes from
which they derive will certainly depend upon the nation's laws. It
would seem that the business-savvy inventor (or investor) would
pursue these opportunities only if avenues of marketability
existed. A local regulation which strictly excludes therapeutic
cloning, prohibits funding, or imposes criminal liability for its
practice can stifle research altogether in that nation. Even more so,
the extraterritorial reach of a nation whose laws criminalize certain
practices certainly can chill scientific research. A private
corporation or any other entity seeking to gain global market-
share, attract venture capital, or expand research opportunity may
want to move its operations to a more permissive nation where a
patent can both be secured and acted upon. Because intellectual
property has global mobility, once the patent is secured, the owner
can operate, perform research, and perhaps conduct clinical trials
in an amicable environment while freely seeking licensing
agreements throughout the global market and lobbying its own or
other governments for relaxed legislation once the technology and
practice is proven. If licensing can remain relatively unencumbered
while preserving its commercial value, greater global access to
research is more likely to be ensured.'28 Ultimately, if funding
cannot be secured, research will be limited.
125. See, e.g., In re Watson, 517 F.2d 465, 476 (Ct. Cust. App. 1975).
126. Cf. In re Fisher, 421 F.3d 1365, 1371 (Fed. Cir. 2005) ("[A]n asserted use must
show that that claimed invention has a significant and presently available benefit to the
public.").
127. Harvard College v. Canada (Commissioner of Patents), [2002] 4 S.C.R. 45, 86.
128. Maria Freire, Dir., Office of Tech. Transfer, Statement of National Institutes of
Health Before Senate Appropriations Subcommittee on Labor, Health and Human
Services, Education and Related Agencies (Aug. 1, 2001), available at
http://stemcells.nih.gov/policy/statements/080101freire.asp.
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VII. TRIPS AND OTHER INTERNATIONAL AGREEMENTS AS A
VEHICLE FOR STEM CELL PATENTS
TRIPS attempts to set minimum standards for protection and
enforcement of intellectual property rights, including patents,
around the world.129 TRIPS recognizes the long-term societal
benefits for innovative medical breakthroughs and encourages
innovation, thereby minimizing the short-term cost to society. The
agreement incorporates the WTO's dispute settlement system and
sets up various exceptions, such as compulsory licensing, which
would prevent abuse of rights or withholding those breakthroughs
which would greatly benefit society.'3 ° TRIPS further requires
WTO Member States to make patents "available for any
inventions, whether products or processes, in all fields of
technology . . ." subject to the normal tests of novelty, non-
obviousness and utility. 131 Article 27 further mandates that
"patents . . . be available and patent rights enjoyable without
discrimination as to the place of invention, the field of
technology[,] and whether products are imported or locally
produced." These provisions make clear that countries are to
extend patent protections regardless of any prior contrary
practice. '
A. Patent Exclusion Under TRIPS
Certain aspects of TRIPS would seem to preclude the free
flow of emerging science, including the patentability of the
therapeutic process, a subject crucial to promoting stem cell
treatment. TRIPS allows nations to exclude from patentability
"diagnostic, therapeutic and surgical methods for the treatment of
humans or animals. 133 Many nations and the European Union
(EU) take advantage of TRIPS's discretionary exclusions from
therapeutic methods." Under this scheme, not only does
129. See WTO SECRETARIAT, GUIDE TO THE URUGUAY ROUND AGREEMENTS 208
(1999).
130. See id. at 215, 219-20.
131. TRIPS, supra note 2, art. 27.1.
132. See PETER-TOBIAS STOLL & FRANK SCHORKOPF, WTO: WORLD ECONOMIC
ORDER, WORLD TRADE LAW 216-17 (2006).
133. TRIPS, supra note 2, art. 27(3)(a).
134. See e.g. The Convention on the Grant of European Patents art. 52(4), Oct. 5, 1973,
1065 U.N.T.S. 255 [hereinafter European Patent Convention].
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international licensing become problematic for licensors in
permissive nations seeking worldwide patent protection of stem
cell treatments, but it could seriously limit marketability by
allowing exclusionary nations to "borrow" a patented method
without risking litigation. Furthermore, process-permissive nations
could adopt exclusionary laws once such treatments are proven
effective in foreign countries, thereby creating an end-run around
the sole purpose of patent protection: to "promote the Progress of
Science and useful Arts" "' by rewarding innovation with a
temporary monopoly.
More important to this discussion, Article 27.2 of TRIPS
allows for the
exclu[sion] from patentability inventions, the prevention
within their territory of the commercial exploitation of
which is necessary to protect ordre public or morality,
including to protect human, animal or plant life or health
or to avoid serious prejudice to the environment, provided
that such exclusion is not made merely because the
exploitation is prohibited by their law.'36
This exclusion is significant because it presupposes a general
rule of patentability,'37 and by its language can exclude any type of
patent. This type of exclusionary principle is not entirely a new
idea. Indeed, the provision was likely inspired by Article 53(a) of
the European Patent Convention (EPC) which excludes European
patents on "inventions the publication or exploitation of which
would be contrary to 'ordre public' or morality .... "' The original
text of the EPC was much broader than TRIPS. First, where
TRIPS focuses on "commercial exploitation," the EPC allowed
exclusions where the mere "publication or exploitation" of the
invention "would be contrary to 'ordre public' or morality."
Second, TRIPS prohibits a country from excluding a patent where-
exploitation was based on its own prohibitions. Under Article 53,
it was not necessary for the exclusion to be grounded in the
excluding country's own laws; rather, a prohibition in "some or all
the Contracting States" could exclude the patent.
135. U.S. CONST., art. I, § 8, cl. 8.
136. TRIPS, supra note 2, art. 27(2).
137. Harvard College v. Canada (Commissioner of Patents), [2002] 4 S.C.R. 45, 96.
138. UNCTAD & ICTSD, supra note 122, at 376; European Patent Convention, supra
note 134, art. 53(a).
524 [Vol. 29:503
2007] Patentability of Stem Cell Research Under TRIPS 525
B. The European Patent Convention's Directive 98/44/EC
The EPC was later enhanced by Council Directive 98/44/EC
to clarify the legal protection of biotechnological inventions across
the EU Member States. 39 This Directive seeks to bring
biotechnology patents and their protection under TRIPS and to
prevent barriers to trade by defining clear principles to govern the
patentability of biotechnological inventions.'40 Notwithstanding
each nation's own patent laws, the Directive excludes therapeutic
and diagnostic processes yet automatically extends patentability to
biological material directly obtained through a process which
enables it to be produced.' Moreover, the Directive seeks to
clarify the exceptions to patentability under the EPC "where ...
commercial exploitation would be contrary to ordre public or
morality" and proscribes any potential patent for the "process for
cloning human beings . . . modifying the . . . genetic identity of
human beings [and] uses of human embryos for industrial or
commercial purposes.""'4 Rule 23(d) was subsequently amended to
the EPC using this language to work in conjunction with Article
53.14 3
C. The History of Morality-Based Exclusions
TRIPS is not self-executing, and unfortunately, a provision
allowing a general exclusion based on ordre public or morality
leaves a gap that is open to interpretation.'" Without a doubt,
these exceptions must be implemented under a nation's own
domestic laws to be effective.' 45 A problem arises in situations
where, as under the EPC, this general language is retained and no
clear definition follows. In particular, a dispute may ensue during
patent prosecution or licensing where definitions from two
different nations conflict. There is no specific WTO decision as to
the precise definition of these terms.'" In the United States, an
139. See Council Directive 98/44/EC, On the Legal Protection of Biotechnological
Invention, pmbl. 1$ 4-5, 1998 O. (L 213) 13 (EC).
140. See id. pmbl. 1$ 4-36, art. 1.
141. Id. pmbl. $ 26, arts. 3, 5. Article 5 permits a patent for "[a]n element isolated from
the human body or otherwise produced by means of a technical process," but it precludes
"the simple discovery of one of its elements." Id. art. 5.
142. Id. art. 6.
143. WARF/Stem Cells, [2006] E.P.O.R. 31,336-38.
144. See In re Rath, 402 F.3d 1207, 1209-10. (Fed. Cir. 2005).
145. UNCTAD & ICTSD, supra note 122, at 375.
146. See id. at 381.
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invention contrary to ordre public has been referred to as
"frivolous or injurious to the well-being, good policy, or sound
morals of society,'' 7 whereas under European law, the definition is
linked to public security and the physical integrity of individuals as
a part of society. '
The European Patent Office (EPO) distinguishes morality
from ordre public. The EPO's Guidelines for the Examination
show that whether a patent will be excluded for moral reasons will
generally depend on whether "it is probable that the public in
general would regard the invention as so abhorrent that the grant
of patent rights would be inconceivable .,19 implying that the
definition imparts regional and cultural distinctions. Although the
United States and Canada have adopted TRIPS, ' they and other
similarly situated nations have not chosen to use ordre public or
morality as a basis for exclusion.' In the United States, a patent
will only be rejected for public policy reasons due to a lack of "any
honest and moral purpose."'52 Nonetheless, the EPC, many civil
law systems, and international agreements continue to rely on this
exclusionary provision. "3
VIII. THE WARF PATENT
The Wisconsin Alumni Research Foundation (WARF)
currently owns U.S. Patent No. 5,843,780, which claims to isolate a
primate embryonic stem cell line. WARF submitted an application
for a patent to the EPO claiming the actual cell cultures and the
method to produce them. The Examining Division refused the
application because it did not comply with Article 53(a) in
conjunction with Rule 23d(c) of the EPC." Specifically, because
the application described the use of human embryos as essential to
the invention as a starting material, the invention fell within the
exception Rule 23d(c) for "uses of human embryos for industrial
147. Id. at 376 (citation omitted).
148. Id. at 379.
149. Id. at 379-80.
150. See, e.g., Uruguay Round Agreement Act, 19 U.S.C. § 3511 (2000).
151. See, e.g., Harvard College v. Canada (Commissioner of Patents), [2002] 4 S.C.R.
45, 96.
152. CHISUM, supra note 119, § 4.03.
153. See Harvard College v. Canada (Commissioner of Patents), [2002] 4 S.C.R. 45, 64.
154. WARF/Stem Cells, [2006] E.P.O.R. 31,333.
155. Id. at 334.
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or commercial purposes."'' 6 On appeal, the Technical Board of
Appeal recognized that "there was no consensus amongst
Contracting States as to the ethical acceptability of using human
embryonic stem cells.' ', 7 Before referring the matter to the
Enlarged Board of Appeal as an "important point of law, the
Technical Board of Appeal began an elaborate discussion of
several important issues.
First, the Board seemed to agree with the appellant that
Article 53(a) was unclear as to the patentability of resulting stem
cells which used to require the destruction of an embryo but does
not after the enactment of Rule 23d. "8 Second, the Board asked
whether the adopted language of Rule 23d would exclude patents
concerning "uses of human embryos for industrial or commercial
purposes."'' 9 It was clear that a narrow interpretation of ordre
public and morality had been adopted,"° however, "use" under
Rule 23d was itself subject to interpretation. Two alternatives were
proposed: (1) a broad interpretation of the statute to include the
unavoidable use of human embryos, and consequently a refusal of
the application on ethical grounds; (2) a narrow interpretation
which would permit the grant. 6' The Board noted that the
legislative history of Directive 98/44/EC showed that the
legislature chose the text "uses of human embryos" as a
replacement for "methods in which human embryos are used" to
ensure that patents on inventions which were applied to an
embryo and useful to it were not excluded.'62
The Board finally concluded that, based on prior decisions, a
narrow interpretation of the EPC provision should prevail after an
intense analysis "by all the usual methods of legal
interpretation.' '63 Such methods would include considering the
words, object and purpose, consequences of a narrow or broad
interpretation, the aspect of legal certainty, and historical
background." Further guidance could also be obtained from the
156. Id.
157. Id. at 338.
158. Id. at 349.
159. Id. at 344.
160. Id. at 337-38.
161. Id. at 337.
162. Id. at 336.
163. Id. at 345.
164. Id.
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principles of interpretation established by the Vienna Convention
on the Law of Treaties.65
Normally, a patent is either granted or rejected based upon its
claims and the category in which it falls: method, utility, or
design.' The Board found that where "ethical objections against
the exploitation of the technology involved . . . the claimed
subject-matter" - in this case, a stem cell line derived from a
previously destroyed embryo - the category of the claim was not
relevant.'67 Compliance can be based on concerns centered on the
invention. This reasoning is consistent with English courts on
similar issues. For example, in Regina (Quintavalle) v. Secretary of
State for Health," the Court of Appeal held that the definition of
"embryo" should be given a purposive construction so that an
organism created by SNCT came within the definition under the
Human Fertilisation and Embryology Act 1990.69 The court in
Quintavalle found it was the capacity to develop into a human
being that mattered, and the legislative policy was that it was
essential to bring the creation and use of embryos under strict
regulatory control for ethical reasons."'70 If the Enlarged Board of
Appeals follows this logic, then it is likely the WARF application
will be excluded under the EPC.
Lastly, the Board elevated the issue of whether Article 53
could forbid patents, on moral ground, which were filed prior to
the enactment of Directive 98/44/EC or to which Rule 23d doesn't
apply.'7' The Board noted that the Guidelines for the Examination
of the EPO promoted a narrow version of ordre public and
morality, and that moral attitudes were constantly changing,
evidenced by the European Parliament's recent vote to permit
public funding for human embryonic stem cell research. 2 Despite
the fact that the appellant's invention used spare embryos
produced by in vitro fertilization donated for research with
165. Id.; see also Convention on the Law of Treaties arts. 31-32, opened for signature
May 23, 1969, 1155 U.N.T.S. 331 [hereinafter Vienna Convention] (entry into force Jan.
27, 1980).
166. See generally CHISUM, supra note 119, § 1.01 (discussing patentable subject
matter).
167. WARF/Stem Cells, [2006] E.P.O.R. 31, 346.
168. R (Quintavalle) v. Secretary of State for Health, [2002] Q.B. 628.
169. Id. at 628.
170. Id. at 640-41.
171. WARF/Stem Cells, [2006] E.P.O.R. 31, 348.
172. Id. at 338.
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informed consent, further stem cell lines would require destruction
of embryos. '73 Here, the Board had its doubts that it could ever be
"ethically acceptable to make a decision by weighing the interests
of human beings who could potentially benefit from the
exploitation of . . . technology against a right, if any, of human
embryos ... to get to life .... Nonetheless, the Board's opinion
emphasized that the EPO's "expertise should remain in the field of
patents, not in resolving controversial moral or ethics issues," and
where a provision of the EPC could be subject to multiple
interpretations a "narrow interpretation avoided the EPO acting
as a moral censor."''
IX. MORALITY-BASED EXCLUSIONS CAN BE BETTER DEFINED BY
CUSTOMARY INTERNATIONAL LAW
There is no doubt that this will not be the first case
concerning the patenting of embryonic stem cells and related
technologies to come before the EPO.'76 The WARF patent
prosecuted in the EU applied only to human embryos that were
already fertilized in vitro.' The case did not discuss the moral
implications of patents derived by SCNT or other processes, and
whether the Enlarged Board of Appeal will broaden its ultimate
decision is unknown. For example, if a purposive construction of
"embryo," as was given by English courts, is undertaken in a
narrow reading of the statute, a patent based on SCNT technology
would most likely be rejected because the embryo created by
SCNT would be capable of human life;'78 the statute would be read
as strictly prohibiting patent based upon the "use" of a human
embryo. On the contrary, a plain-meaning construction would not
define an embryo created by SCNT as a "human embryo" and
would likely permit the patent. Alternatively, a purposive
construction of "embryo" undertaken in a broad reading of the
173. Id. at 341.
174. Id. at 348.
175. Id. at 337.
176. See id. at 339.
177. The United States Patent and Trademark Office granted requests from
Foundation Taxpayer and Consumer Rights (FTCR) and the Public Patent Foundation
(PUBPAT) to reexamine its patent. See Warf Stem Cell Patents to be Re-examined at
Request of FTCR, PUBPAT: Patent Office Finds "Substantial Question" Regarding
Validity of WARF's Claims, PUBPAT, Oct. 3, 2006, http://www.pubpat.org/
warfstemcellgranted.htm.
178. WARF/Stem Cells, [2006] E.P.O.R. 31,337-38.
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statute would require an extensive understanding, and perhaps
speculation, of legislative intent before a decision could be made.
A. Morality-Based Exclusions Will Depend on Local or Regional
Custom
Other nations are certain to enact legislation regarding
morality in the execution of their duties under TRIPS. In addition,
adherence to international agreements and resulting change are
both unavoidable. Whether it is a stem cell line, altered gene,
chimeric research, or SCNT process, each new promise of medical
breakthroughs brings with it new ethical dilemmas. With the
Council of Europe Convention on Human Rights and Biomedicine
forbidding SCNT on the one hand, and California declaring it a
fundamental right on the other, the status of therapeutic cloning is
uncertain. It is quite possible that the EPC may soon come under
scrutiny in *light of the condemnation of SCNT or therapeutic
cloning practices by many Member States.
The fact that each nation or region has a different set of
cultural beliefs, practices, religion, and laws only exacerbates the
problem. The purpose of TRIPS is to unify legislation globally to
provide a high standard of intellectual property protection. '79 What
is moral to one, however, may most likely not be moral to others.
Many nations abhor cultural relativism - the principle that a
human's beliefs and activities should be interpreted in terms of his
or her own culture. It is not hard to see why many countries would
have serious reservations against a mandate to accept norms
contrary to their own, especially those dealing with "morality.'. 8
Morality can be classified as either private or public morality;
where public morality is characterized by the "ideals or general
moral beliefs of a society.""'1 By its own definition, morality
includes the "totality of accepted norms" deeply rooted in a
particular region or culture." Therefore, signatories must not only
enact clear patent laws that precisely state the limits of protection,
but must also have a solid justification based upon their regional
179. STOLL & SCHORKOPF, supra note 132, at 216.
180. Relevant definitions of morality include "a doctrine or system of ideas concerned
with conduct" and "conduct conforming to the customs or accepted standards of a
particular culture or group." WEBSTER'S THIRD NEW INTERNATIONAL DICTIONARY OF
THE ENGLISH LANGUAGE, UNABRIDGED 1469 (2002).
181. BLACK'S LAW DICTIONARY 812 (7th ed. 2000).
182. UNCTAD & ICTSD, supra note 122, at 380.
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and cultural definition of morality. Where domestic legislation falls
short, regional norms must play their part in interpretation.
B. Customary International Law Aiding Interpretation
Article 31 of the Vienna Convention states that "[a] treaty
shall be interpreted in good faith in accordance with the ordinary
meaning to be given to the terms of the treaty in their context and
in the light of its object and purpose. 183 Subsection (c) further
mandates that interpretation "shall . . . take [] into account,
together with the context ... any subsequent agreement between
the parties regarding the interpretation of the treaty or the
application of its provisions.""4 Additionally, the WTO Dispute
Settlement Understanding (DSU), Article 3(2) clearly indicates
that existing provisions under WTO agreements are to be clarified
"in accordance with customary rules of interpretation of public
international law...... There has been significant commentary
seeking to establish that these provisions "should not be
considered in isolation of general international law."'86  In
particular, there is "a presumption that the WTO system is to be
interpreted consistently with general international law, and that
the customary rule is to apply unless it can be shown that such an
application would undermine the object and purpose of the WTO
system."'" Of course, this proposition presupposes that any
relevant customary norm has legal status on the parties to begin
with,ln and that the parties have not "contracted out" of the
customary rule.89  Where TRIPS is vague, either in its
183. Vienna Convention, supra note 165, art. 31
184. Id. art. 31 1 3(c).
185. Understanding on Rules and Procedures Governing the Settlement of Disputes,
art. 3.2, Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade Organization,
Annex 2, Legal Instruments - Results of the Uruguay Round, 33 I.L.M. 1226 (1994).
186. See Philippe Sands, Treaty, Custom and the Cross-Fertilization of International
Law, 1 YALE HUM. RTS. & DEV. L.J. 85, 95 (1998). The WTO/GATT is not grounded in
custom, and thus references to international norms have in the past only been on rare
occasion. See id. at 93.; see also David Palmeter & Petros Mavroidis, The WTO Legal
System: Sources of Law, 92 AM. J. INT'L L. 398,406 (1998). In spite of this, the WTO Panel
and Appellate Body have expressed an increased willingness to apply and interpret
WTO/GATT rules in a broader international context. Sands, supra note 186, at 97.
187. Sands, supra note 186, at 104; see also JOOST PAUWELYN, CONFLICT OF NORMS
IN PUBLIC INTERNATIONAL LAW 253-54 (2003) (contending that the principle of conflict
avoidance poses an inherent limit on treaty interpretation).
188. See Sands, supra note 186, at 102.
189. PAUWELYN, supra note 187, at 252.
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implementation under domestic law or by judicial interpretation,
customary international law should be allowed to supplement its
provisions where appropriate and in such a way that it does not
conflict with any other TRIPS provisions or international
agreements between contracting parties.
C. Patent Exclusions Should Be Necessary to Preserve the
Customary Norm
TRIPS itself prescribes that the use of an invention may be
prohibited by law cannot, by itself, affect its patentability. But
before a patent can be declared ineligible, Article 27.2 imparts a
"necessity test" which requires a specific link between morality
and the commercial exploitation of a patent.' Therefore, it would
seem that the provision would not be applicable to actual stem cell
research as long as the research is not conducted with commercial
intent. Patent law itself does not require commercialization, except
in the unusual situation where the patent right is given in exchange
for government funding and a promise to commercialize it. In the
real world, however, patents and commercialization are often
intertwined. The potential of commercialization enables channels
of funding which in turn fuels research - it is very much a
dependent cycle. If a form of stem cell research is deemed immoral
under TRIPS, then it may not patentable. Nonetheless, any
company not intending to capitalize on it would still be free to
undertake the research. Yet, without the ability to capitalize on
the end product, research is likely to be frustrated.
It is hard to reason that banning a practice may be "necessary
to protect ... morality" when a nation and its courts have already
deemed the practice permissible in the private sector under
government supervision. For instance, just because the Quintavalle
court determined that SCNT was subject to regulation under the
Human Fertilisation and Embryology Act 1990 did not mean that
SCNT was not permissible within the country itself. "2 The court
recognized that the research would only be subject to state
regulation. "3 TRIPS mandates that an exclusion cannot be justified
merely because commercialization of the invention is prohibited
190. TRIPS, supra note 2, art. 27(2).
191. UNCTAD & ICTSD, supra note 122, at 378, 381.
192. R (Quintavalle) v. Secretary of State for Health, [2002] Q.B. 628, 628.
193. See id.
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by law, much less its potential commercialization. Accordingly,
allowing a nation to exclude an invention from patentability
merely because it has regulated, but has not banned, the area of its
practice would create an end-run around Article 27 - a result
which the drafters surely did not intend. The only convincing
reason for exclusion, therefore, can be found only where the
exclusion is necessary to prevent a contradiction of the accepted
norms deeply rooted in a nation's culture and values.
D. A Collaborative Solution
Unless TRIPS is modified to impose a clear definition of its
moral restrictions, a solid framework built upon an understanding
of emerging customary international law should be drawn upon to
guide global legislators and patent prosecutors in dealing with the
potential conflicts between morality and emerging technologies
such as SCNT-like processes and their derivatives. Thus, in the
area of stem cell research, a collaborative solution will require the
acceptance of four key principles:
1. Principles of Embryonic Research
In embryonic research, the principles of informed donor
consent, proscription against the commercialization of embryonic
materials, and prohibition of research on an embryo beyond
fourteen days are customary norms and emerging rules of
customary international law.
2. Customary Norms
Morality, as defined in TRIPS, is seen as a regional ideology
or as adhering to a custom. Therefore, the rules above should
supplant, or elaborate on, what the customary norm of the region
is, and help to define what is permissible to society in the area of
embryonic stem cell research.
3. Interpretation of a Nation's Domestic Laws
Patent law itself should not be primarily concerned with
morality, and the patentability of any invention dealing with
embryonic research should be based entirely upon the
interpretation of a nation's domestic laws as part of, but not
exclusive of, its international obligation under TRIPS.
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4. Customary International Law
Where domestic laws are unclear or reference to TRIPS is
necessary, interpretation of provisions such as or in accordance
with Article 27.2 should be consistent with customary international
law. In the case of embryonic research, the relevant customary
international law would include informed donor consent, a
proscription against the commercialization of embryonic materials,
and a prohibition of research on an embryo beyond fourteen days;
so long as the implemented rule is not contrary to any specific
agreement between contracting parties.
The judicial interpretation of domestic legislation consistent
with international obligations under customary international law is
certainly not a new idea.'9" Such a scheme over embryonic stem cell
research would help guide interpretation of the vaguer laws
currently in existence and help legislatures to draft new laws which
adhere to the norms of their society. In fact, it is by this ongoing
process of adjudication that the normative content of international
norms can continue to be further developed and solidified.'9"
X. CONCLUSION
Morality is an amorphous concept, taking on different forms
in different areas of the world. Whether intentional or not,
morality-based limitations imposed by TRIPS and other
international agreements may inhibit the patent process.
Patentability of inventions in one nation or another plays an
important role in the global marketplace and upon the future
availability of funding. Funding fuels innovation. Therefore,
inventors need to understand both domestic and international laws
in order to realize their dreams and capitalize upon them. If the
concept of informed donor consent, prohibition against the
commercialization of embryonic materials, and the fourteen day
rule are recognized as customary international law, then these
basic principles can be used as bases for drafting legislation that
must ultimately confront emerging stem cell technology and the
unavoidable litigation that will ensue from it. These principles may
even help a nation to set policy or decide whether to exclude or
criminalize a particular technology or practice altogether.
194. See Sands, supra note 186, at 104-05.
195. See PAUWELYN, supra note 187, at 93.
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Moreover, patents can be drafted with these considerations in
mind to not only ensure compliance with international law, but
also quite possibly with morality itself.
Each new technological development in the global arena
brings the possibility for positive change. As with other patents,
there should be a symbiotic relationship between new innovations
in stem cell research and the international normalization of patent
law. A harmony between customary international law, TRIPS, and
the domestic legislation which follows can do no less than
stimulate the marketability of new products on a global scale. With
marketability comes innovation, and with each new innovation
there is the tremendous potential for another addition to the
feedback loop fueling global acceptance.
Kenneth C. Cheney

